Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

Barbara Pro*, Brian Leber, Mitchell Smith, Luis Fayad, Jorge Romaguera, Fredrick Hagemeister, Alma Rodriguez, Peter McLaughlin, Felipe Samaniego, James Zwiebel, Adriana Lopez, Larry Kwak, Anas Younes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

Oblimersen sodium plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) patients. Oblimersen was administered as a continuous intravenous infusion at a daily dose of 3 mg/kg/d for 7 d on alternate weeks for 3 weeks. Rituximab was given at a weekly dose of 375 mg/m2 for six doses. Patients with stable disease or objective response were allowed to receive a second course of treatment. The overall response rate (ORR) was 42% with 10 complete responses (CR) and eight partial responses (PR). Twelve (28%) patients achieved a minimal response or stable disease. Among the 20 patients with follicular lymphoma the ORR was 60% (eight CR, four PR). Three of the responders were refractory to prior treatment with rituximab, and two of the responses occurred in patients who had failed an autologous stem cell transplant. Median duration of response was 12 months. Most toxicities were low grade and reversible. In conclusion, oblimersen sodium can be safely combined with rituximab. The combination appears to be most beneficial in patients with indolent NHL and warrants further investigation in a large randomized trial.

Original languageEnglish (US)
Pages (from-to)355-360
Number of pages6
JournalBritish Journal of Haematology
Volume143
Issue number3
DOIs
StatePublished - Nov 2008

Keywords

  • Non-Hodgkin lymphoma
  • Oblimersen sodium
  • Recurrent B-cell NHL
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this